<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005303</url>
  </required_header>
  <id_info>
    <org_study_id>RGHT000395</org_study_id>
    <nct_id>NCT01005303</nct_id>
  </id_info>
  <brief_title>Micronutrient Supplementation in Patients With Heart Failure</brief_title>
  <acronym>MINT-HF</acronym>
  <official_title>A Trial of Micronutrient Supplementation in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Belfast Health and Social Care Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Belfast Health and Social Care Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is some evidence to suggest that patients with heart failure may have a reduced dietary&#xD;
      intake of vitamins and essential minerals (micronutrients) and that this may worsen the&#xD;
      function of the heart. This study is designed to investigate if supplementation with&#xD;
      micronutrients (including high-dose vitamin D) will improve the function of the heart in&#xD;
      patients with heart failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular Ejection Fraction</measure>
    <time_frame>1 Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac Volumes</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Inflammation</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Oxidative Stress</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Cardiac Function</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Functioning</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Micronutrient</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 Tablet Daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Forceval plus 50 micrograms Vitamin D3</intervention_name>
    <description>Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily</description>
    <arm_group_label>Micronutrient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  New York Heart Association Class II and III&#xD;
&#xD;
          -  Already on or tried on best known medical treatment (ACE inhibitor and beta-blocker)&#xD;
&#xD;
          -  Stable for a period of at least 6 weeks&#xD;
&#xD;
          -  Left ventricular ejection fraction less than or equal to 45%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of significant alcohol ingestion (more than 40 units per week)&#xD;
&#xD;
          -  Severe renal dysfunction (GFR less than 30ml/min)&#xD;
&#xD;
          -  Severe hepatic dysfunction (known liver disease or transaminases greater than 3 times&#xD;
             the upper limit of normal)&#xD;
&#xD;
          -  Atrial fibrillation (in the absence of a pacemaker)&#xD;
&#xD;
          -  Frequent ventricular ectopics&#xD;
&#xD;
          -  On waiting list for cardiac transplantation&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Estimated life span less than 12 months&#xD;
&#xD;
          -  Already taking a multivitamin/mineral supplement&#xD;
&#xD;
          -  Already taking a vitamin-D containing fish oil&#xD;
&#xD;
          -  Woman of child-bearing potential&#xD;
&#xD;
          -  History of renal stones, hypercalcaemia, sarcoidosis, haemochromatosis or lactose&#xD;
             intolerance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal McKeown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Belfast Health and Social Care Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Harbinson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Belfast Health and Socail Care Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michelle McKinley, PhD</last_name>
    <role>Study Director</role>
    <affiliation>The Queen's Univeristy of Belfast</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>October 29, 2009</study_first_submitted>
  <study_first_submitted_qc>October 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2009</study_first_posted>
  <last_update_submitted>January 27, 2015</last_update_submitted>
  <last_update_submitted_qc>January 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Belfast Health and Social Care Trust</investigator_affiliation>
    <investigator_full_name>Pascal McKeown</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Micronutrients</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Physical Functioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 28, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

